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The mechanisms underlying apparently
spontaneous autoimmune diseases, such
as autoimmune hemolytic anemia (AIHA)
in New Zealand Black (NZB) mice, are
unknown. Here, we determine the contri-
bution of the dominant red blood cell
(RBC) autoantigen, the anion exchanger
protein Band 3, to the development of
NZB autoimmune responses. The ap-
proach was to prevent Band 3 expression
in NZB mice by disrupting the AE1 gene.
AE1/NZB mice produced RBC autoanti-
bodies at the same levels as the wild-type
strain, but they differed in recognizing
antigens that correspond to glycophor-
ins, rather than Band 3. Splenic T-helper
(Th) cells from wild-type NZB mice prolif-
erated strongly against multiple Band 3
peptides, particularly the dominant
epitope within aa861-874. This helper re-
sponse was severely attenuated in AE1/
animals, leaving only weak proliferation
to peptide aa861-874. The results demon-
strate that the defect in self-tolerance in
NZB AIHA is directed to the RBC type, and
is not specific for, or dependent on, Band
3. However, the predisposition to RBC
autoimmunity may be focused onto Band
3 by weak Th cell cross-reactivity be-
tween the helper dominant epitope and
an exogenous antigen. The redundancy
of the major autoantigen illustrates the
requirement for specific therapy to in-
duce dominant forms of tolerance, such
as T-cell regulation. (Blood. 2007;110:
4511-4517)
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Introduction
The underlying mechanisms that drive damaging responses in
autoimmune disease are poorly understood. Valuable insights have
been obtained from the study of murine models. For example,
genetic analyses have shown that different loci govern susceptibil-
ity to autoimmunity and determine which organs are affected,1
while functional studies have identified particular autoantigens and
highlighted the role of T-cell subsets in pathogenesis.2 However,
the stimuli that initiate and perpetuate apparently spontaneous
autoaggression remain the subject of controversy.
Autoimmune hemolytic anemia (AIHA) is a classic example of
an antibody-mediated autoimmune disease, and provides an oppor-
tunity to study the development of specific pathogenic responses,
since the major human3-5 and murine6,7 autoantigens have been
identified. Efforts to identify possible mechanisms of autoaggres-
sion often focus on spontaneous AIHA in the New Zealand Black
(NZB) strain of mouse. The mice develop signs of anemia by 5 to
6 months of age due to the production autoantibodies that bind red
blood cells (RBCs) and cause erythrophagocytosis.8 Band 3, the
RBC anion exchanger protein (AE1), is the dominant autoanti-
gen.6,7,9,10 Eluted autoantibodies exclusively immunoprecipitate
Band 3 from murine RBCs,6 and 4 of 5 IgG anti–RBC monoclonal
autoantibodies (mAbs) derived from NZB mice react with this
antigen.9,10 The autoantibody response is helper dependent11,12 and
Band 3 is also the major target for autoreactive T-helper (Th)
cells.7,13-16 Splenic CD4 T cells from NZB mice, but not H-2–
matched healthy strains, proliferate in vitro in response to Band
3,7,13 and initial epitope mapping studies identified a number of
stimulatory peptides, of which aa861-874 was consistently the
most potent.14 We have now identified the MHC binding and T-cell
receptor (TCR) contact residues within Band 3 aa861-874,15 and
confirmed that this epitope is dominant in vivo, since the adminis-
tration of peptides containing the core sequence modulated autoan-
tibody production and disease in NZB mice.16
There are a number of hypotheses put forward to explain the
development of autoimmune diseases such as AIHA.17 One
widely held belief is that disease is triggered by changes in the
presentation of autoantigens from the target cells in such a way
as to overcome self-tolerance. For example, infection or inflam-
mation may activate antigen presenting cells (APCs) via innate
pathways,18 leading to more effective autoantigen presentation
to T cells, or may skew processing pathways within APCs to
generate self-peptides that are less subject to central tolerance.19
A second explanation for autoaggression is that the damaging
responses are a manifestation of polyclonal activators such as
superantigens or mitogens, or of a generalized failure to control
lymphoproliferation.20 Another commonly held view is that
pathogenic autoimmunity is driven by antigens in the environ-
ment, particularly microbial proteins, which cross-react with the
target autoantigen.18,19,21 This contention is supported by the
induction of murine models, such as experimental autoimmune
encephalomyelitis (EAE),22 by immunization with foreign homo-
logues of self-proteins, but there is little evidence for cross-
reactivity or mimicry as a cause of apparently spontaneous
autoimmune disease.17,23
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One approach to testing these hypotheses is to determine the
contribution of the dominant autoantigen to the induction of disease.
Expression of any particular autoantigen in vivo may be unnecessary if
disease is driven by aberrant immune processing and presentation of the
target cell type, or by polyclonal activation, but would be required if the
response were initiated by specific cross-reactivity with an environmen-
tal agent. The aim of the current work was therefore to test whether the
development of AIHA in NZB mice is dependent on the expression of
Band 3, or whether the spontaneous autoimmune response can switch to
other RBC antigens. These questions were addressed by disrupting the
AE1 gene to prevent Band 3 expression, and then comparing autoanti-
body and Th responses in wild-type and AE1/NZB mice.
Materials and methods
Mice
NZB and healthy control BALB/c mice were maintained under specific
pathogen-free conditions in isolators in the animal facilities at the universi-
ties of Bristol and Aberdeen. All work was carried out under United
Kingdom Home Office Project License approval.
Peters et al24 provided 129/SV-C57BL/6J strain mice that lack the RBC
anion exchanger Band 3 (129/SV-C57BL/6J.AE1/) due to targeted
disruption of the AE1 gene. Failure to express Band 3 prevents the
formation of important structural links with the internal membrane skel-
eton, and results in the production of fragile RBCs of abnormal morpholo-
gy.24 However, mice homozygous for the null mutation can survive to
adulthood, despite failure to express both RBC Band 3 and the related
isoform of the protein from the kidney.24 Heterozygous AE/ mice have a
normal phenotype and were used for a breeding program to back-crossing
the mutant allele onto the NZB strain. Heterozygous (AE1/) offspring
were identified by extracting genomic DNA from tail samples (NucleonHT
kit; Scotlab, Glasgow, United Kingdom) and using PCR to amplify a
fragment specific for the mutant allele.24 After at least 20 successive cycles
of back-crossing, heterozygotes were then intercrossed to generate off-
spring that include homozygous AE1/ NZB mice lacking Band 3. These
were selected by demonstration of the mutant, but not wild-type, allele by
polymerase chain reaction (PCR) and by the absence of Band 3 after sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) analysis
of RBC membranes (Figure 1).
RBC membrane preparations
Erythrocyte ghosts were prepared by hypotonic lysis of washed RBCs.3,6
The protein concentration of each sample was determined by the method of
Bradford.25
Antigens and mitogen
Murine RBC antigens were prepared and their purity assessed as described
previously.7 Briefly, murine Band 3 was purified by anion exchange
chromatography from healthy murine RBC membranes that had been
stripped of peripheral proteins and detergent solubilized in 1% C12E8
(Sigma, Poole, United Kingdom). Residual detergent was removed by cold
acetone precipitation of the protein, which was dialyzed extensively against
phosphate-buffered saline (PBS), pH 7.4, before addition to cultures at a
final concentration of 10 g/mL. The mitogen Concanavalin A (Con A;
Sigma), was used to stimulate positive control cultures at an optimal final
concentration of 1 g/mL.
Peptides
A panel of 92 15-mer peptides with 5 or 6 amino acid overlaps, corre-
sponding to the complete sequence of murine Band 3,26 was synthesized by
a multiple-peptide solid-phase method using fluorenylmethoxycarbonyl-
polyamide chemistry (Department of Biochemistry, University of Bristol,
Bristol, United Kingdom). The purity of the peptides was checked by mass
spectroscopy. Peptides were used to stimulate cultures at 20 g/mL, which
has been found to be the optimal concentration in previous epitope mapping
studies.14-16
Immunization with Band 3 protein
Groups of 6-week-old NZB mice were immunized at the base of the tail by
subcutaneous injection of Band 3 protein (100 g/mouse) administered as
an emulsion in complete Freund adjuvant (Sigma).
Culture and stimulation of T cells
As described elsewhere7,13-16 splenic T cells were obtained and cultured
together in the presence of antigen, peptides, or mitogen in a humidified
atmosphere of 5% CO2 and 95% air at 37°C. On day 5 of culture,
proliferation was estimated from the incorporation of tritiated (3H) thymi-
dine (Amersham, Aylesbury, United Kingdom) in triplicate samples using a
1450 Microbeta Liquid Scintillation Counter (LKB Wallac, Turku, Fin-
land). Results are presented as stimulation index (SI), representing the ratio
of proliferation in stimulated cultures versus unstimulated control wells. As
previously, an SI greater than 3 was interpreted as a significant positive
response.7,13-16,27
Flow cytometry
The antibodies used were directly conjugated with either fluorescein isothiocya-
nate or phycoerythrin (anti-mouse CD4, CD8, and CD71) and were purchased
from Pharmingen (Oxford, United Kingdom). Cell samples containing 106 cells
were labeled with antibodies at optimal concentrations in the dark for 30 minutes
on ice and washed. A benchtop FACScan analyzer IV (Becton Dickinson,
Cowley, United Kingdom) was used with a 488 nm argon ion laser to detect
green and red fluorescence, dead cells were excluded from analysis by gating on
forward and side light scatter properties, and the data were analyzed with MAC
Cell Quest (Becton Dickinson).
Measurement of IgG subclasses bound to RBCs
The number of IgG molecules of each subclass bound to the surface of
RBCs was determined using a quantitative and sensitive cellular enzyme-
linked immunosorbent assay (ELISA) based on a direct enzyme-linked
antiglobulin test (DELAT) developed in our laboratories and described in
detail elsewhere.7,16,28 Briefly, a 2% suspension of washed, glutaraldehyde-
fixed RBCs was added to duplicate wells of round-bottomed microtiter
plates and incubated with subclass-specific sheep anti–mouse IgG antibody
(The Binding Site, Birmingham, United Kingdom). After a further incuba-
tion with alkaline-phosphatase–conjugated donkey antisheep antibody
(Sigma), the RBCs were allowed to react with phosphatase substrate
solution (p-nitrophenyl phosphate; Sigma). The supernatant was transferred
into flat-bottomed microtiter plates and the optical density (OD) measured
at 405 nm (Titertek Multiscan II; Labsystems, Basingstoke, United
Kingdom). The number of molecules of each murine IgG subclass bound to
Figure 1. Lack of Band 3 expression in AE/ gene-disrupted NZB mice. Lanes
A-D illustrate ethidium bromide staining of agarose gel–fractionated PCR products
corresponding to the disrupted (A,B, 600 base pairs) or wild-type (C,D, 400 base
pairs) AE1 gene sequence using samples of genomic DNA from heterozygous AE/
(A,C) or homozygous (B,D) AE/ NZB mice. Lanes E and F illustrate SDS-PAGE
analysis of wild-type (E) or AE/ (F) murine RBC membrane preparations stained for
protein with Coomassie Blue. Each track was loaded with approximately 20 g
protein. The position of Band 3, with an apparent molecular mass of 100 kDa, is
indicated (➝).
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the RBCs was calculated by interpolation from a standard curve generated
by tanning normal RBCs with a known concentration of each purified IgG
subclass7,16,28 (Sigma).
Elution of autoantibody from RBCs
Autoantibody was eluted from washed RBCs by ether treatment.3,6 Eluates
were stored at 20°C and, after thawing, any precipitated material was
removed by centrifugation.
SDS-PAGE
SDS-PAGE was performed in 10% or 12% polyacrylamide gels as
described previously3,6,29,30 according to the method of Laemmli,31 using
the Mini Protean II (Bio-Rad, Hemel Hempstead, United Kingdom).
Apparent molecular masses were calculated from migration relative to
standard protein markers (SDS-6H; Sigma). Where necessary, gels were
developed with Coomassie Brilliant Blue or periodic acid–Schiff (PAS)
stains, respectively, for protein- or glycoprotein-containing bands.32
Immunoprecipitation of RBC antigens
Biotin-labeled murine RBC autoantigens or rat antigens were immunopre-
cipitated.3,6,29,30 Briefly, washed RBCs from healthy mice were biotinylated
and sensitized with antibody from sera or RBC eluates. After incubation
with rabbit antiserum against murine IgG Fc (Nordic, Maidenhead, United
Kingdom), the RBCs were lyzed in hypotonic buffer and the membranes
dissolved in PBS containing 2% Triton X100 (Sigma). Solubilized immune
complexes were immobilized on sepharose–protein A beads (Sigma) and
eluted into gel sample buffer for SDS-PAGE. Proteins separated by
SDS-PAGE were transferred to nitrocellulose by Western blotting,33 using a
semidry apparatus (Pharmacia-LKB, Uppsala, Sweden) with a continuous
buffer system as described by the manufacturer. Biotin-labeled RBC
proteins bound to nitrocellulose were detected by incubation with peroxidase-
conjugated Extravidin (Sigma) and luminography.3,6,29,30,34 Blots were
soaked in a freshly prepared luminescent substrate solution,34 sandwiched
between polythene sheets and exposed to film (Hyperfilm MP; Amersham)
in an x-ray cassette without intensifying screens.
Results
Generation of AE1/ NZB mice
The first step toward determining whether NZB AIHA is dependent
on the dominant autoantigen, Band 3, was to generate genetically
modified AE1/ mice that lack this protein. A targeted disruption
of the AE1 gene was introduced into 129/SV-C57BL/6J mice,24
back-crossed onto the NZB strain for at least 20 generations, and
the offspring intercrossed to produce AE1/ NZB mice. It has
previously been demonstrated that mice homozygous for the null
gene express no detectable Band 3 transcript or protein by Northern
or Western blotting, respectively.24 AE1/ mice for the current
study were selected from the litters of AE1/ intercrosses using
PCR of genomic DNA24 to identify the null mutation and the
absence of wild-type AE1 gene, and by the lack of Band 3 seen after
SDS-PAGE fractionation of RBC membranes (Figure 1).
Anti–RBC antibody responses in gene-disrupted AE1/ NZB
mice that lack the dominant Band 3 autoantigen
If the defect in self-tolerance in NZB AIHA is not Band 3–specific,
then the autoimmune response in AE1/ NZB mice will switch to
other RBC targets. However, if NZB disease results from poly-
clonal B-cell activation, then Band 3 antibodies should be produced
despite absence of the antigen. On the other hand, if the initiation of
autoimmunity is dependent on Band 3, for example, because it
cross-reacts with an environmental agent, then there should be no
disease in mice that lack the autoantigen. To test these predictions,
we first asked whether anti–RBC antibodies are reduced or absent
in NZB mice when the Band 3 autoantigen is not expressed, and
then determined the specificity of any such antibodies.
The levels of RBC-bound IgG were compared in age-matched,
wild-type, and AE1/ NZB mice using a highly sensitive DELAT.28 It
can be seen from Figure 2 that similar levels of all 4 IgG isotypes were
present on the surface of RBCs from both wild-type and AE1/ NZB
mice. Although the lack of Band 3 causes hemolysis through increased
RBC fragility,24 autoantibody production in AE1/ NZB mice is
associated with more severe anemia than is seen in control nonautoim-
mune AE1/mice. Mean hematocrit in AE1/NZB mice (n 6) was
11.0% plus or minus 2.5% standard deviation (SD), compared with
19.1% plus or minus 1.5% SD AE1/ in animals (n 5) from the
129/SV-C57BL/6J strain.
The detection of high levels of RBC-bound IgG in AE1/ NZB
mice raises the question as to the specificity of this immunoglobu-
lin. A related question is whether, in the absence of Band 3, the
genetically modified animals make anti–Band 3 antibodies, which
would be unable to bind their RBCs and therefore remain free in the
serum. To address these issues, sera and antibodies eluted from the
RBCs of AE1/ NZB mice were tested for the ability to
immunoprecipitate labeled membrane antigens from healthy mu-
rine RBCs (Figure 3). Figure 3A illustrates the electrophoretic
mobility of the major protein (i) and glycoprotein (ii) components
Figure 2. Autoantibody responses are equally strong in wild-type and AE/
NZB mice. Comparison of number of IgG molecules of each isotype present on
RBCs from individual wild-type (n  16) or AE/ (n  6) NZB mice aged 20 weeks.
The IgG levels were measured by DELAT. The background levels on the RBCs of
healthy control mice are less than 380 molecules IgG1, less than 250 molecules
IgG2a, less than 280 molecules IgG2b, and less than 500 molecules IgG3.
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fractionated from wild-type murine RBC membranes. Figure 3B
demonstrates that, as previously reported, positive control eluate
from the wild-type NZB RBC immunoprecipitated one major
protein species (i) corresponding in SDS-PAGE migration to Band
3. In contrast, no antibodies of this specificity were detected in sera
(iii,iv) or RBC eluates (v,vi) from AE1/ NZB mice. However,
IgG in these samples instead precipitated a doublet of RBC proteins
with apparent molecular masses of 70 kDa to 85 kDa in SDS-
PAGE. A comparison with stained RBC proteins and glycoproteins
(Figure 3A) reveals that the precipitated bands correspond in
mobility either to the internal membrane skeleton proteins Bands
4.1 and 4.2, or to the highly glycosylated cell-surface glyoco-
phorins.32 The diffuse nature of the precipitated bands is consistent
with a high degree of glycosylation32 and, of the candidates, only
the glycophorins would be available on intact RBCs for antibody
binding.32 To demonstrate that AE1/ NZB mice retain the ability
to make antibodies specific for Band 3, despite the absence of a
spontaneous response, a control group of genetically modified
animals was immunized with the purified protein as a foreign
antigen. Figure 3B (vii,viii) shows that, in addition to the proteins
of 70 kDa to 85 kDa, sera from immunized AE1/ NZB mice also
precipitated an RBC membrane component of 100 kDa, correspond-
ing in SDS-PAGE migration to Band 3.
Characterization of Th responses to Band 3 in wild-type
NZB mice
We have previously reported that splenic Th cells from NZB mice
proliferate in vitro in response to Band 3 protein purified from
RBCs,7,13 and to a dominant epitope contained within peptide
aa861-874.14-16 It was now necessary to generate a complete helper
epitope map of Band 3 in wild-type NZB mice with AIHA, for
comparison with responses in gene-disrupted AE1/ NZB mice
that lack the autoantigen. A panel of 92 overlapping peptides
corresponding to the complete sequence of Band 3 was screened
for the ability to stimulate the in vitro proliferation of splenic
T cells from NZB mice aged 20 weeks. Figure 4 summarizes the
results from a series of up to 8 repeated experiments, and
demonstrates that the T cells are capable of responding to a total of
more than 20 peptides as judged by a stimulation index of 3 or
Figure 3. The spontaneous anti-RBC antibody response in AE/ NZB mice
targets antigens other than Band 3. (A) SDS-PAGE analysis of wild-type murine
RBC membrane preparations stained for protein with Coomassie Blue (lane i), or for
glycoprotein with PAS (lane ii). Each track was loaded with approximately 20 g
protein. Major protein and glycophorin bands of the RBC membranes are labeled32
and the apparent molecular masses are indicated in kDa. (B) Immunoprecipitation of
biotin-labeled antigens from healthy murine RBCs. Immunoprecipitates were ana-
lyzed by SDS-PAGE, blotted onto nitrocellulose, and developed by luminography.
Biotin-labeled RBCs were incubated with samples as follows: (i) positive control
autoantibody-containing RBC eluate from wild-type NZB mice; (ii) negative control
RBC eluate from healthy mice; (iii,iv) sera from individual AE/ NZB mice; (v,vi) RBC
eluates from individual AE/ NZB mice; (vii,viii) control sera from individual AE/
NZB mice immunized with Band 3. The apparent molecular mass of the specific
bands precipitated is indicated in kDa. Lanes i, ii, iii, vi, vii, and viii are from different
blots.
Figure 4. Proliferative responses of T cells from NZB
mice to a panel of peptides spanning the sequence of
the dominant murine RBC autoantigen Band 3, and
against the purified protein. Each bar represents the
stimulation index of the peak response of T cells pooled
from the spleens from individual mice aged 20 weeks.
Each of the 92 peptides was tested on between 5 and
8 mice. The horizontal line indicates the minimum level of
a positive response (SI  3).
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above. There were some differences in the profiles of stimulatory
peptides between individual mice, but, as reported previously14-16
peptide 87 (aa861-874) invariably elicited strong responses. Puri-
fied Band 3 also potently stimulated proliferation in all experi-
ments. Consistent with earlier studies,14-16 responses to Band 3 and
peptides were predominantly mediated by T cells of the CD4
helper phenotype, as determined by subset depletion experiments,
flow cytometric analysis, and the ability of antibodies against MHC
class II molecules to block proliferation (results not shown).
Characterization of Th responses to Band 3 in gene-disrupted
AE1/ NZB mice that lack the autoantigen
If autoaggressive Th cells in NZB mice are primed by polyclonal
activators or cross-reactive environmental agents, rather than by
Band 3, then there should be residual helper responses to Band 3
epitopes in the absence of the antigen in vivo. Gene-disrupted
AE1/ NZB mice, matched in age with the wild-type NZB mice
studied in Figure 4, were killed and their splenic Th cells tested for
the ability to respond in vitro to the panel of Band 3 peptides and
purified antigen (Figure 5). It can be seen that, in comparison with
the results obtained using wild-type NZB mice, splenic Th cells
from AE1/ animals were far less responsive to Band 3 protein
and peptides. Thus, AE1/ Th cell proliferation against purified
Band 3 and the subdominant peptides such as 12 (aa110-125) and
31 (aa301-317) was ablated or very weak. However, although
responses to peptide 87 (aa861-874) were also markedly attenu-
ated, significant reactivity to this dominant sequence was retained
in all but one of the gene-disrupted animals.
It could be argued that the reduced proliferation against Band 3
epitopes in AE1/ NZB mice is not specific, but due to general
immunosuppression. However, the mitogen Con A was equally
effective in stimulating splenic T cells from wild-type or gene-
disrupted NZB mice, and immunization of AE1/ NZB mice with
Band 3 restored in vitro responses to Band 3 and multiple peptides,
including the dominant sequence aa861-874 (results not shown).
The finding that the dominant Band 3 peptide 87 (aa861-874)
stimulates residual Th responses in vitro in AE1/ NZB mice, albeit
more weakly than in the wild-type strain, raises the possibility that the
cells are primed in vivo by another antigen. Interrogation of the
SwissProt database reveals considerable potential for such cross-
reactivity with, for example, multiple bacterial sequences identified that
share all or some of the key MHC anchor and TCR contact residues with
the autoreactive Th cell epitope in peptide 87.15
Discussion
This study of NZB mice genetically engineered to lack the
dominant RBC autoantigen Band 3 has allowed dissection of the
underlying mechanisms of spontaneous AIHA. The main result
is that induction of NZB AIHA is not dependent on expression of
the major autoantigen. In its absence, no detectable antibodies
are made to Band 3, and the corresponding helper response is
greatly attenuated, but, instead, high levels of autoantibodies
with other RBC specificities are generated. The immune defect
is therefore specific for the RBC type, rather than for the
dominant autoantigen. Such plasticity of the autoaggressive
response has implications for the specific treatment of AIHA and
other autoimmune diseases.
The shift in the specificity of the autoantibody response in
AE/ NZB mice indicates that the potential for autoaggression
is not limited to Band 3, and is consistent with the view that a
variety of antigens from the target cell may be processed and/or
presented in a more immunogenic fashion to drive autoimmune
disease.2,17,19 For example, aberrant handling of RBCs by APCs
would be expected to predispose to autoimmune responses
against a range of potential autoantigens.17,19 Such a change may
arise from activation of APCs, or recruitment of nonprofessional
APC types, in response to innate immune signals.17-19 Immuno-
precipitation experiments revealed that the major autoantigens
bound by autoantibody in AE/ NZB mice correspond to the
glycophorins, which are heavily glycosylated proteins ex-
pressed on the RBC surface.32 Glycophorins are important
autoantigens in many other examples of AIHA, including
Figure 5. Proliferative responses of T cells from
AE/ NZB mice to a panel of peptides spanning the
sequence of murine RBC Band 3, and against the
purified protein. Each bar represents the stimulation
index of the peak response of T cells from individual mice
aged 20 weeks. Each of the 92 peptides was tested on
6 mice. The horizontal line indicates the minimum level of
a positive response (SI  3).
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disease in some human patients,3,4,35,36 dogs,30 and in experimen-
tal AIHA induced in mice by immunization with rat RBCs.29,37
Although studies of mAbs from NZB mice support the identifi-
cation of Band 3 as the dominant RBC autoantigen, they also
reveal the potential for autoantibodies with other, minor speci-
ficities to be present in NZB AIHA.9,10 Presumably such species,
which are not detectable in the polyclonal response of wild-type
NZB mice, expand greatly in the absence of Band 3. Autoanti-
body production in both wild-type and Band 3–deficient NZB
mice was associated with anemia. Although the relative pathoge-
nicity of the 2 antibody responses was not compared in detail,
the levels bound to RBCs and the proportions of each IgG
subclass were similar, and these factors are important determi-
nants of hemolysis.13,16 The correspondence in the ratios of IgG
isotypes also indicates that the Th subtype of the responses was
unaffected by the switch in specificity.
The lack of anti–Band 3 antibody production in AE/ NZB
mice demonstrates that the response to this antigen in the
wild-type strain is not a manifestation of polyclonal B-cell
activation by, for example, superantigens.20 This confirms the
results of a previous approach to determining the molecular
mechanisms responsible for autoantibody production in NZB
mice, based on characterization of anti–RBC mAbs derived
from NZB splenocytes.9,10,38,39 The IgVH gene sequences of
these mAbs, most of which are Band 3–specific,9,10 show
evidence of somatic mutation,38,39 indicating that affinity matu-
ration has occurred and that the autoantibody production is
therefore antigen driven. The current work allows a further
conclusion to be drawn: that the antigen responsible for driving
the B-cell response in wild-type NZB mice is Band 3 itself.
Cross-reactivity or molecular mimicry between environmen-
tal and autoantigens has often been proposed to be a mechanism
underlying apparently spontaneous autoimmune disease.18,19,21,40
Such cross-reactivity may provide increased levels of particular
antigenic sequences, or greater avidity of recognition, to over-
come self-tolerance, and, in the case of mimicry by infectious
agents, innate stimuli may enhance such immunogenicity.18
However, since AIHA in NZB mice is not dependent on
expression of Band 3, it is now clear that the disease can develop
without the need to invoke any cross-reactivity between environ-
mental agents and this dominant RBC autoantigen. The possibil-
ity remains open that the same cross-reactive stimulus initiates
responses to both Band 3 and glycophorin.
Given that Band 3 is not essential for NZB AIHA, and that
the response can switch to other autoantigens, the question
arises as to why Band 3 is the dominant target in wild-type NZB
mice. One explanation is that dominance simply reflects the fact
that there are more copies of Band 3 on the RBC surface than
any other protein,32 and that the response in AE/ NZB mice
switches to glycophorins as the next most abundant32 candidate
antigens. However, analysis of Th responses in AE/ NZB mice
reveals a new possibility: that cross-reactivity with environmen-
tal agent(s) primes a weak Th response against the major Band 3
epitope, which, in the absence of the autoantigen, cannot spread
to other determinants. Such epitope spreading, the recruitment
of Th cells with further specificities for the initiating antigen, is
a typical feature of autoimmune diseases,2,17,19 and is likely to be
important in providing sufficient help to drive autoantibody
production41,42 and pathology. In the scenario suggested here,
weak cross-reactivity with a single self-epitope acts to focus a
tendency toward RBC autoimmunity onto a particular autoanti-
gen, rather than representing a primary or sufficient cause of
disease. Several examples of homology between the dominant
RBC auto-epitope on Band 3 and bacterial sequences were
identified, and it remains to be confirmed whether these, or any
other environmental agents, are responsible for priming autore-
active Th cells in NZB mice.
Previous examples of murine genetic modification or muta-
tions that prevent autoantigen expression have been described in
other models of autoimmune disease.22 EAE can be induced by
immunization with any one of several myelin proteins, and so
lack of a particular target, such as myelin basic protein in mutant
shiver mice, does not prevent disease induced by the other
antigens.22 However, all such models are experimentally in-
duced, and the current study of NZB AIHA is the first to
demonstrate redundancy of a major autoantigen in a spontane-
ous autoimmune disease.
The ability of autoaggressive responses in NZB mice to switch to
targets other than the dominant autoantigen is relevant to the develop-
ment of specific immunotherapy for autoimmune conditions. Thus, even
where a single dominant target for pathogenic responses can be clearly
identified, reinstatement of tolerance to that autoantigen alone may not
be an effective treatment. It will be essential to focus on the induction
forms of active tolerance based on regulation,17,42 which may have
bystander effects on other associated autoantigens, rather than simply
the elimination or silencing of lymphocytes with one set of specificities.
Acknowledgments
The authors are very grateful to Dr Luanne L. Peters of the Jackson
Laboratory, Bar Harbor, ME, for provision of gene-disrupted mice.
This work was funded by grants from the Wellcome Trust,
United Kingdom (R.N.B.).
Authorship
Contribution: A.M.H., F.J.W., and C.-R.S. performed research,
analyzed data, and wrote the paper; C.R., L.B., and A.D.
collected and analyzed data; S.J.U. and C.J.E. designed re-
search; R.N.B. designed research, collected and analyzed data,
and wrote the paper.
A.M.H., F.J.W., and C.-R.S. contributed equally to this work.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: R.N. Barker, Department of Medicine &
Therapeutics, Institute of Medical Sciences, University of Aber-
deen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom; e-mail:
r.n.barker@abdn.ac.uk.
References
1. Vyse TJ, Todd JA. Genetic analysis of autoim-
mune disease. Cell. 1996;85:311-318.
2. Elson CJ, Barker RN. Helper T cells in antibody-
mediated, organ specific autoimmunity. Curr Opin
Immunol. 2000;12:664-669.
3. Barker RN, Casswell K, Reid ME, Sokol RJ, El-
son CJ. Identification of autoantigens in autoim-
mune haemolytic anaemia by a non-radioisotope
immunoprecipitation method. Br J Haematol.
1992;82:126-132.
4. Leddy JP, Falany JL, Kissel GR, Passador ST,
Rosenfeld SI. Erythrocyte membrane proteins reac-
tive with human (warm reacting) anti-red cell autoan-
tibodies. J Clin Invest. 1993;91:1672-1680.
5. Barker RN, Hall AM, Standen GR, Jones J, Elson
CJ. Identification of T-cell epitopes on the Rhesus
polypeptides in autoimmune hemolytic anemia.
Blood. 1997;90:2701-2715.
4516 HALL et al BLOOD, 15 DECEMBER 2007  VOLUME 110, NUMBER 13
For personal use only.on October 19, 2018. by guest  www.bloodjournal.orgFrom 
6. Barker RN, de Sa Oliveira GG, Elson CJ, Lydyard
PM. Pathogenic autoantibodies in the NZB
mouse are specific for Band 3 protein. Eur J Im-
munol. 1993;23:1723-1726.
7. Perry FE, Barker RN, Mazza G, et al. Autoreac-
tive T cell specificity in autoimmune hemolytic
anemia of the NZB mouse. Eur J Immunol. 1996;
26:136-141.
8. DeHeer DH, Edgington TS. Cellular events asso-
ciated with the immunogenesis of anti-erythrocyte
autoantibody responses of NZB mice. Transplant
Rev. 1976;31:116-155.
9. de sa Oliveira GG, Izui S, Ravirajan CT, et al. Di-
verse antigen specificity of erythrocyte-reactive
monoclonal autoantibodies from NZB mice. Clin
Exp Immunol. 1996;105:313-320.
10. Diulio NA, Fairchild RL, Caulfield MJ. The anti-
erythrocyte autoimmune response of NZB mice:
identification of two distinct autoantigens. Immu-
nology. 1997;91:246-251.
11. Chen S, Takeoka Y, Ansari AA, Boyd R, Klinman
DM, Gershwin ME. The natural history of disease
expression in CD4 and CD8 gene-deleted New
Zealand Black (NZB) Mice. J Immunol. 1996;157:
2676-2684.
12. Oliveira GGS, Hutchings PR, Roitt IM, Lydyard
PM. Production of erythrocyte autoantibodies in
NZB mice is inhibited by CD4 antibodies. Clin
Exp Immunol. 1994;96:297-304.
13. Shen C-R, Mazza G, Perry FE, et al. T-helper 1
dominated responses to erythrocyte Band 3 in
NZB mice. Immunology. 1996;89:195-199.
14. Shen CR, Wraith DC, Elson CJ. Splenic but not
thymic autoreactive T cells from New Zealand
Black mice respond to a dominant erythrocyte
Band 3 peptide. Immunology. 1999;96:595-599.
15. Shen CR, Ward FJ, Devine A, et al. Characteriza-
tion of the dominant autoreactive T-cell epitope in
spontaneous autoimmune haemolytic anaemia of
the NZB mouse. J Autoimmun. 2002;18:149-157.
16. Shen C-R, Youssef A-R, Devine A, et al. Peptides
containing a dominant T-cell epitope from red cell
Band 3 have in vivo immunomodulatory proper-
ties in NZB mice with autoimmune hemolytic ane-
mia. Blood. 2003;102:3800-3806.
17. Barker RN, Vickers MA, Ward FJ. Controlling au-
toimmunity: lessons from the study of red blood
cells as model antigens. Immunol Lett. 2007;108:
20-26.
18. Ohashi PS, DeFranco AL. Making and breaking
tolerance. Curr Opin Immunol. 2002;14:744-759.
19. Elson CJ, Barker RN, Thompson SJ, Williams
NA. Immunologically ignorant autoreactive T
cells, epitope spreading and repertoire limitation.
Immunol Today. 1995;16:71-76.
20. Dziarski R. Autoimmunity: polyclonal activation or
antigen induction? Immunol Today. 1988;9:340-
342.
21. Todd JA, Steinman L. The environment strikes
back. Curr Opin Immunol. 1993;5:863-865.
22. Yoshizawa I, Bronson R, Dorf ME, Abromson-
Leeman S. T-cell responses to myelin basic pro-
tein in normal and MBP-deficient mice. J Neuro-
immunol. 1998;84:131-138.
23. Nicholson LB, Wraith DC. T-cell receptor degen-
eracy: the dog that did not bark: adaptation of the
self-reactive T-cell response to limit autoimmune
disease. Mol Immunol. 2004;40:997-1002.
24. Peters LL, Shivdasani RA, Liu SC, et al. Anion
exchanger 1 (band 3) is required to prevent eryth-
rocyte membrane surface loss but not to form the
membrane skeleton. Cell. 1996;86:917-927.
25. Bradford MM. A rapid and sensitive method for
the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. Anal
Biochem. 1976;72:248-254.
26. Kopito RR, Lodish HF. Primary structure and
transmembrane orientation of the murine anion
exchange protein. Nature. 1985;316:234-238.
27. Devereux G, Hall AM, Barker RN. Measurement
of T-helper cytokines secreted by cord blood
mononuclear cells in response to allergens. J Im-
munol Methods. 2000;234:13-22.
28. Mazza G, Day MJ, Barker RN, Corato A, Elson
CJ. Quantitation of erythrocyte-bound IgG sub-
class autoantibodies in murine autoimmune hae-
molytic anaemia. Autoimmunity. 1996;23:245-
255.
29. Barker RN, Casswell KM, Elson CJ. Identification
of murine erythrocyte autoantigens and cross-
reactive rat antigens. Immunology. 1993;78:568-
573.
30. Barker RN, Gruffydd-Jones TJ, Stokes CR, Elson
CJ. Identification of autoantigens in canine auto-
immune haemolytic anaemia. Clin Exp Immunol.
1991;85:33-40.
31. Laemmli UK. Cleavage of structural proteins dur-
ing the assembly of the head of bacteriophage
T4. Nature. 1970;227:680.
32. Barker RN. Electrophoretic analysis of erythro-
cyte membrane proteins and glycoproteins from
different species. Comp Haematol Int. 1991;1:
155-160.
33. Burnette WN. “Western blotting”: electrophoretic
transfer of proteins from sodium dodecyl sulfate-
polyacrylamide gels to unmodified nitrocellulose
and radiographic detection with antibodies and
radioiodinated protein A. Anal Biochem. 1981;
112:195-203.
34. Laing P, Parkar BA, Culbert EJ, Watt GJ, Elson
CJ. Identification of rat erythrocyte antigens with
a new non-radioactive immunoprecipitation tech-
nique. Scand J Immunol. 1987;25:613-62.
35. Garratty G, Arndt P, Domen R, et al. Severe auto-
immune hemolytic anemia associated with IgM
warm autoantibodies directed against determi-
nants on or associated with glycophorin A. Vox
Sang. 1997;72:124-130.
36. Johnson ST, McFarland JG, Kelly KJ, Casper JT,
Gottschall JL. Transfusion support with RBCs
from an Mk homozygote in a case of autoimmune
hemolytic anemia following diphtheria-pertussis-
tetanus vaccination. Transfusion. 2002;42:567-
571.
37. Barker RN, Shen C-R, Elson CJ. T-cell specificity
in murine autoimmune haemolytic anaemia in-
duced by rat red blood cells. Clin Exp Immunol.
2002;129:208-213.
38. Reininger L, Shibata T, Ozaki S, Shirai T, Jaton
JC, Izui S. Variable region sequences of patho-
genic anti-mouse red blood cell autoantibodies
from autoimmune NZB mice. Eur J Immunol.
1990;20:771-777.
39. Scott BB, Sadigh S, Stow M, Mageed RA, An-
drew EM, Maini RN. Anti-mouse red blood cell
monoclonal antibodies use functionally rear-
ranged genes from the VH J558 family and are
derived from the CD5- B-lymphocyte subpopula-
tion. Immunology. 1993;79:568-573.
40. Barker RN, Elson CJ. Multiple self epitopes on
the Rhesus polypeptides stimulate immunologi-
cally ignorant human T cells in vitro. Eur J Immu-
nol. 1994;24:1578-1582.
41. Stott L-M, Barker RN, Urbaniak SJ. Mapping allo-
reactive T cell epitopes on the Rhesus D protein.
Blood. 2000;96:4011-4019.
42. Hall AM, Ward FJ, Vickers MA, Stott LM, Urba-
niak SJ, Barker RN. Interleukin-10-mediated
regulatory T-cell responses to epitopes on a hu-
man red blood cell autoantigen. Blood. 2002;100:
4529-4536.
AUTOIMMUNE RESPONSES IN AUTOANTIGEN-DEFICIENT MICE 4517BLOOD, 15 DECEMBER 2007  VOLUME 110, NUMBER 13
For personal use only.on October 19, 2018. by guest  www.bloodjournal.orgFrom 





Urbaniak, Christopher J. Elson and Robert N. Barker
Andrew M. Hall, Frank J. Ward, Chia-Rui Shen, Cliff Rowe, Laura Bowie, Anne Devine, Stanislaw J.
 
hemolytic anemia: effects on autoantibody and T-helper responses
Deletion of the dominant autoantigen in NZB mice with autoimmune
 
http://www.bloodjournal.org/content/110/13/4511.full.html
Updated information and services can be found at:
 (1159 articles)Red Cells    
 (5627 articles)Immunobiology and Immunotherapy    
 (5175 articles)Free Research Articles    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on October 19, 2018. by guest  www.bloodjournal.orgFrom 
